Navigation Links
Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
Date:5/30/2008

ectives of the Phase 1 open-label, dose-escalation study are to evaluate the safety and tolerability of HGS1029 as monotherapy in patients with advanced solid tumors, and to select a recommended dose for Phase 2 studies. Secondary objectives include documenting possible anti-tumor activity and determining HGS1029's pharmacokinetic profile. HGS1029 will be administered as a 15-minute infusion once weekly for 3 consecutive weeks followed by a week off. Up to 40 patients will be treated in the study, with 15-20 patients treated in the dose-escalation phase.

About the HGS Oncology Portfolio

HGS is investing strategically to expand and advance its oncology portfolio around its leading expertise in the apoptosis pathway. HGS has initiated new chemotherapy combination trials of HGS-ETR1 (mapatumumab), added the new opportunity to develop and commercialize HGS1029 and other IAP inhibitors, and reacquired the rights to its TRAIL receptor antibodies. HGS-ETR1, the Company's antibody to TRAIL receptor 1, is the most advanced of any product in development that targets the TRAIL apoptosis pathway.

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon(R) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing.

ABthrax(TM) (raxibacumab) is in late-stage development for the treatment of inhalation anthrax, and the Company is on track to begin the delivery in fall 2008 of 20,000 doses of ABthrax to the Strategic National Stockpile under a contract entered into with the U.S. Government in June 2006. Other HGS drugs in clinical devel
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... --NOWDiagnostics Inc., based in Springdale, Ark. , ... Canada , a move that brings the company ... have greater access to information concerning their health. ... blood-based rapid tests that allow health care providers to ... ailments and diseases. ZBx Corporation, a Toronto ...
(Date:9/1/2015)... , Sept. 1, 2015  Dr. Cindy ... Labs , the cannabis testing subsidiary of DigiPath, Inc. ... Group about the lack of consistency in today,s ... online resource for medical cannabis information, she explained that ... because their lack of uniform requirements makes standardization impossible. ...
(Date:9/1/2015)... 1, 2015   Alpha Imaging LLC , a leading distributor ... announced today that they have been awarded exclusive rights to ... in Michigan.   The new territory supplements Alpha Imaging,s existing Shimadzu sales ... Ohio , Indiana , ... , West Virginia , Delaware ...
Breaking Medicine Technology:NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 3Alpha Imaging Expands Shimadzu Territory 2
... Medical Systems (NYSE: VAR ) today announced that ... N.A. to repurchase $250 million of its common stock under ... revolving credit facility with Bank of America, N.A. to increase ... Under the accelerated repurchase agreement, Varian will pay $250 ...
... Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced ... trial evaluating the safety and pharmacokinetics of dabigatran ... valves.(1) The 12-week study will compare three doses ... 300mg bid) to warfarin in patients with both ...
Cached Medicine Technology:Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 2Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 2Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 4Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 5Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 6Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 7
(Date:9/1/2015)... ... September 01, 2015 , ... Celebrity hairstylist and Beauty Gives Back Art ... Behind the Fashion” on Thursday, Oct. 1, at the La Valencia Hotel. The presentation, ... the collaboration between fashion and professional hair, makeup and nail design. , The ...
(Date:9/1/2015)... ... September 01, 2015 , ... Pharmaceutical ... different malignancies. Some options for cancer treatment are available belonging to various ... approach is necessary for effective treatment. Several molecules have been discovered out ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... Vending Machine,” is still strongly maintaining her firm’s success in the hair care ... In her upcoming city-to-city tour, Ellis will be providing “Look and learn” live ...
(Date:9/1/2015)... ... September 01, 2015 , ... PetPace, the provider of an ... and activity, today announced its integration with leading veterinary Practice Management Software vendor ... hospital Practice Management Software packages in the US. Practice Management Software helps veterinarians ...
(Date:9/1/2015)... , ... September 01, 2015 , ... Zecurion, a leading ... , its groundbreaking new version of endpoint DLP developed specifically for Mac OS. , ... which more than 100 IT and information security professionals had participated. The beta test ...
Breaking Medicine News(10 mins):Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:Zecurion Announces Endpoint Security for Mac 2
... 2009 The first results of the first European survey ... at the 6th congress of the European Federation of Chapters ... , Previous surveys have looked at the overall management of ... study to look in detail at Breakthrough Cancer Pain (BTCP) ...
... ... relationship to offer comprehensive staffing, scheduling, and credentialing software to nurse staffing ... no additional charge. , ... Nashville, TN (Vocus) September 11, 2009 -- BlueSky Synergy, LLC (BlueSky) and People ...
... ... Yum-Yum D3 Gummies, Yum-Yum GOS Syrup (prebiotic fiber syrup), and Yum-Yum Zymes at the ... and Exhibition Center in Boston, MA, September 24-26, 2009. , ... Los Angeles, CA (PRWEB) September 11, 2009 ...
... ... dental group practice in central North Carolina, today announced the addition of Dr. Brian Cahill ... ... pleased to announce that Dr. Brian Cahill has joined their cosmetic and family dental practice. ...
... , , NEW YORK, Sept. 10 ... The Mount Sinai Medical Center describe the Community Diabetes and ... program which was designed specifically for people from the vulnerable Latino ... Twenty-five patients from The Mount Sinai Medical Center were randomly selected ...
... speed immunity, experts say , THURSDAY, Sept. 10 (HealthDay ... vaccine conducted in Australia and Britain show that a ... virus within about 10 days. , That,s a potentially ... would be needed to provide full immunity to the ...
Cached Medicine News:Health News:First results from major European patient survey show devastating impact of living with breakthrough cancer pain 2Health News:BlueSky Synergy, a Division of Amistaff Healthcare Technology, and People 2.0 Global Partner to Provide Complimentary Staffing Software to Participating Companies 2Health News:BlueSky Synergy, a Division of Amistaff Healthcare Technology, and People 2.0 Global Partner to Provide Complimentary Staffing Software to Participating Companies 3Health News:Jarrow Formulas, Inc. to Unveil Children's Natural Health Products at Upcoming Natural Products Expo East Show in Boston 2Health News:Jarrow Formulas, Inc. to Unveil Children's Natural Health Products at Upcoming Natural Products Expo East Show in Boston 3Health News:Dr. Brian Cahill Joins Research Triangle Dental 2Health News:Dr. Eliscer Guzman, with The Mount Sinai Medical Center, Join Forces to Celebrate the Community Diabetes and Cardiovascular Care Program's Graduation Ceremony on September 16th 2Health News:One Dose of Swine Flu Vaccine Offers Protection: Studies 2Health News:One Dose of Swine Flu Vaccine Offers Protection: Studies 3
... a whole blood hematology control manufactured specifically ... 120, and the Coulter AcT5diff instruments. The ... white cell differential, positioning the populations within ... systems. The product offers 105-day closed-vial stability ...
... assayed hematology control, offers complete assay values ... with the Coulter GENS, STKS, MAXM and ... stability, 105-day closed-vial stability and is available ... 4.0ml pierceable cap vial is compatible with ...
Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
Diagnosoft HARP is designed for rapid analysis of tagged cardiac MR images using the HARP technology, which is packaged into an intuitive, easy-to-use graphic user interface....
Medicine Products: